Literature DB >> 15691231

Pathogenesis of malignant pleural mesothelioma.

Marie-Claude Jaurand1, Jocelyne Fleury-Feith.   

Abstract

Malignant pleural mesothelioma (MPM) results from neoplastic transformation of mesothelial cells. Past asbestos exposure represents the major risk factor for MPM, as the link between asbestos fibres and MPM has been largely proved by epidemiological and experimental studies. Asbestos fibres induce DNA and chromosome damage linked to oxidative stress following phagocytosis. Recently, simian virus 40 (SV40) has been implicated in the aetiology of MPM. The origin of human infection has been associated with SV40-contaminated polio vaccines, although to date, no epidemiological data supports this hypothesis. SV40 may act as a coactivator of asbestos in mesothelial oncogenesis. The transforming potency of SV40 results from the activity of two viral proteins, large T and small t antigens. SV40 infection stimulates production of growth factors elsewhere implicated in autocrine growth of mesothelioma cells and inactivates RASSF1, a gene silenced in MPM. Roles for ionising radiation, chemicals or genetic factors have also been suggested from the observation of sporadic MPM cases or animal studies. Genetic alterations in the tumour suppressor genes, P16/CDKN2A and neurofibromatosis 2 (NF2), are found both in human MPM and in asbestos-exposed Nf2-deficient mice. MPM is still of great international concern. Despite a ban on asbestos use in Western countries, the incidence of MPM is increasing, due to the long delay between asbestos exposure and diagnosis. Moreover, asbestos is still used in developing countries. The implication of other risk factors, especially SV40, supports a need for further research into MPM.

Entities:  

Mesh:

Year:  2005        PMID: 15691231     DOI: 10.1111/j.1440-1843.2005.00694.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  16 in total

1.  Transforming growth factor-β-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway.

Authors:  Gengyun Wen; Mei Hong; Bingyan Li; Wupeng Liao; Simon K Cheng; Burong Hu; Gloria M Calaf; Ping Lu; Michael A Partridge; Jian Tong; Tom K Hei
Journal:  Int J Oncol       Date:  2011-06-23       Impact factor: 5.650

2.  Inflammatory Cytokines Contribute to Asbestos-Induced Injury of Mesothelial Cells.

Authors:  Milena Marques Pagliarelli Acencio; Barbara Soares; Evaldo Marchi; Carlos Sergio Rocha Silva; Lisete Ribeiro Teixeira; V C Broaddus
Journal:  Lung       Date:  2015-06-10       Impact factor: 2.584

3.  Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.

Authors:  Adam Moore; Bryan Bennett; Gavin Taylor-Stokes; Laura McDonald; Melinda J Daumont
Journal:  BMC Cancer       Date:  2022-06-23       Impact factor: 4.638

Review 4.  The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms.

Authors:  Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Tumour Biol       Date:  2013-10-01

5.  Novel role of toll-like receptor 3, RIG-I and MDA5 in poly (I:C) RNA-induced mesothelial inflammation.

Authors:  Markus Wörnle; Matthias Sauter; Kathrin Kastenmüller; Andrea Ribeiro; Maximilian Roeder; Holger Schmid; Florian Krötz; Thomas Mussack; Roland Ladurner; Thomas Sitter
Journal:  Mol Cell Biochem       Date:  2008-11-13       Impact factor: 3.396

Review 6.  Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.

Authors:  J Green; Y Dundar; S Dodd; R Dickson; T Walley
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

7.  Osteopontin mRNA expression by rat mesothelial cells exposed to multi-walled carbon nanotubes as a potential biomarker of chronic neoplastic transformation in vitro.

Authors:  Sreepradha Sridharan; Alexia Taylor-Just; James C Bonner
Journal:  Toxicol In Vitro       Date:  2021-02-27       Impact factor: 3.685

8.  CDKN2A Determines Mesothelioma Cell Fate to EZH2 Inhibition.

Authors:  Giulia Pinton; Zhuo Wang; Cecilia Balzano; Sara Missaglia; Daniela Tavian; Renzo Boldorini; Dean A Fennell; Martin Griffin; Laura Moro
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

9.  Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.

Authors:  Filip Mundt; Henrik J Johansson; Jenny Forshed; Sertaç Arslan; Muzaffer Metintas; Katalin Dobra; Janne Lehtiö; Anders Hjerpe
Journal:  Mol Cell Proteomics       Date:  2013-12-20       Impact factor: 5.911

10.  Childhood cancers: what is a possible role of infectious agents?

Authors:  Kenneth Alibek; Assel Mussabekova; Ainur Kakpenova; Assem Duisembekova; Yeldar Baiken; Bauyrzhan Aituov; Nargis Karatayeva; Samal Zhussupbekova
Journal:  Infect Agent Cancer       Date:  2013-12-10       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.